unige:160857 | 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework | Leuzy, A; Ashton, N J; Mattsson-Carlgren, N; Dodich, Alessandra; ... Hansson, O |
unige:160679 | Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework | Chiotis, Konstantinos; Dodich, Alessandra; Boccardi, Marina; Festari, Cristina; ... Nordberg, Agneta |
unige:160864 | Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework | Wolters, E E; Dodich, Alessandra; Boccardi, M; Corre, Julie; ... Ossenkoppele, R |
unige:160859 | Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework | Bischof, Gérard N; Dodich, Alessandra; Boccardi, Marina; van Eimeren, Thilo; ... Drzezga, Alexander |
unige:153505 | Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison | Altomare, Daniele; Caprioglio, Camilla; Assal, Frédéric; Allali, Gilles; ... Garibotto, Valentina |
unige:151586 | The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update | Boccardi, Marina; Dodich, Alessandra; Albanese, Emiliano; Gayet-Ageron, Angèle; ... Garibotto, Valentina |
unige:160856 | The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers | Ashton, N J; Leuzy, A; Karikari, T K; Mattsson-Carlgren, N; ... Hansson, O |